CIRM Funded Clinical Trials

A phase I/II study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) for the treatment of adults with COVID-19


Xiaokui Zhang
Disease Area: 
COVID-19
Investigator:
Institution:
Award Value:
$750,000
Trial Sponsor:
Celularity Inc
Trial Stage: 
Phase 1/2
Trial Status: 
Recruiting
Targeted Enrollment:
86
ClinicalTrials.gov ID:
Details: 

This trial will use blood stem cells obtained from the placenta to generate natural killer (NK) cells, a type of white blood cell that is a vital part of the immune system, and administer them to patients with COVID-19.  NK cells play an important role in defense against cancer and in fighting off viral infections.  The goal is to administer these cells to locate the active sites of COVID-19 infection and destroy the virus-infected cells. 

Design: 

Phase I/II Study

Goal: 

Safety, tolerability, and efficacy